Clinical Trial Detail

NCT ID NCT03261999
Title Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
Recruitment Completed
Gender male
Phase Phase III
Variant Requirements No
Sponsors Foresee Pharmaceuticals Co., Ltd.
Indications

prostate carcinoma

Therapies

Leuprolide

Age Groups: adult senior

No variant requirements are available.